Teva Pharmaceuticals (TEVA)

• Market cap: $19.4B
• 1 day: 2.12%
• 5 days: 2.36%
• 1 month: 0.78%
• 3 months: 8.90%
• 6 months: -5.33%
• Year to date: -20.70%
• 1 year: 2.93%
• 5 years: 46.11%
• 10 years: -75.55%
• Sector: Healthcare
• Industry: Drug Manufacturers - Specialty & Generic

About: Teva Pharmaceutical Industries, based in Israel, is the leading generic drug manufacturer in the world. Teva derives half of its sales from North America and makes up a high-single-digit percentage of the total number of generic prescriptions in the US. It also has a significant presence in Europe, Japan, Russia, and Israel. Besides generics, Teva has a portfolio of innovative medicines and biosimilars in three main therapeutic areas: the central nervous system with Copaxone, Ajovy, and Austedo; respiratory with Qvar and ProAir; and oncology with Truxima, Herzuma, and Bendeka/Treanda. Teva also sells active pharmaceutical ingredients, offers contract manufacturing services, and owns Anda, a US-based generic and specialty drug distributor.

Employees: 35,686

Fund manager confidence

Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)

40% more call options, than puts

Call options by funds: $515M | Put options by funds: $369M

3.42% more ownership

Funds ownership: 58.66% [Q4 2024] → 62.08% (+3.42%) [Q1 2025]

4% more repeat investments, than reductions

Existing positions increased: 191 | Existing positions reduced: 183

4% less funds holding

Funds holding: 571 [Q4 2024] → 547 (-24) [Q1 2025]

19% less first-time investments, than exits

New positions opened: 70 | Existing positions closed: 86

26% less capital invested

Capital invested by funds: $14.7B [Q4 2024] → $10.9B (-$3.74B) [Q1 2025]

28% less funds holding in top 10

Funds holding in top 10: 36 [Q4 2024] → 26 (-10) [Q1 2025]

Research analyst outlook

5 Wall Street Analysts provided 1 year price targets over the past 3 months

• Low target: $22 30% upside
• Avg. target: $23 39% upside
• High target: $25 48% upside

5 analyst ratings

• positive: 5 100%
• neutral: 0 0%
• negative: 0 0%

UBS Ashwani Verma	36% upside $23	Buy Maintained	26 Jun 2025
Goldman Sachs Matt Dellatorre	42% upside $24	Buy Initiated	6 Jun 2025
Truist Securities Les Sulewski	48% upside $25	Buy Initiated	28 May 2025
JP Morgan Chris Schott	36% upside $23	Overweight Upgraded	12 May 2025
B of A Securities Jason Gerberry	30% upside $22	Buy Maintained	8 May 2025